Valuation : HLS Therapeutics Inc.

Market Cap 84.39M 72.72M 68.18M 62.24M 117M 8.07B 118M 809M 316M 4.07B 317M 310M 13.5B P/E 2026 *
-13.2x
P/E 2027 * -39x
Enterprise Value 84.39M 72.72M 68.18M 62.24M 117M 8.07B 118M 809M 316M 4.07B 317M 310M 13.5B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.3x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day+2.43%
1 week+1.07%
Current month-9.76%
1 month-10.82%
3 months-17.43%
6 months-15.78%
Current year-21.37%
1 week 3.64
Extreme 3.64
3.92
1 month 3.56
Extreme 3.56
4.29
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap.
20/08/26 Buy

Chief Executive Officer

500 0.0016%
17/08/26 Buy

Chief Executive Officer

2,000 0.0064%
31/07/26 TaxCompany 1,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+2.43%+1.07%-29.29%-13.86% 84.39M
+0.32%+4.02%+30.11%+111.86% 104B
-0.25%+2.20%+57.65%+161.10% 54.55B
+2.29%-7.59%-14.10%+239.24% 22.12B
+0.86%+1.36%-12.10%-14.93% 8.15B
-0.07%-1.57%-37.56%-28.02% 7.21B
-1.05%+0.93%+2.68%+18.68% 6.36B
+0.76%-4.32%-14.68%-30.59% 6.34B
+0.54%+2.93%-1.58%+21.54% 5.2B
+2.78%+16.03%+284.53%+455.00% 4.29B
Average +0.86%+2.07%+26.57%+92.00% 21.85B
Weighted average by Cap. +0.41%+3.12%+30.82%+125.39%

Financials

2026 *2027 *
Net sales 58.44M 50.36M 47.21M 43.1M 81.19M 5.59B 81.45M 560M 219M 2.82B 219M 215M 9.35B 65.03M 56.03M 52.54M 47.96M 90.34M 6.21B 90.63M 623M 243M 3.14B 244M 239M 10.4B
Net income -5.47M -4.71M -4.42M -4.03M -7.6M -523M -7.62M -52.43M -20.46M -264M -20.54M -20.09M -875M -2.16M -1.87M -1.75M -1.6M -3.01M -207M -3.02M -20.75M -8.1M -104M -8.13M -7.95M -346M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
28/08/26 CA$3.790 +2.43% 52,047
27/08/26 CA$3.700 +1.37% 34,900
26/08/26 CA$3.650 -4.95% 17,582
25/08/26 CA$3.840 +4.07% 36,505
24/08/26 CA$3.690 -1.60% 113,781
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.728USD
Average target price
5.286USD
Spread / Average Target
+93.78%

Quarterly revenue - Rate of surprise